Blood. 2011 Feb 10;117(6):2009-11. Epub 2010 Oct
20.
Translocation t(14;16) and
multiple myeloma: is it really an independent
prognostic factor?
Avet-Loiseau H, Malard F, Campion L, Magrangeas
F, Sebban C, Lioure B, Decaux O, Lamy T, Legros
L, Fuzibet JG, Michallet M, Corront B, Lenain P,
Hulin C, Mathiot C, Attal M, Facon T, Harousseau
JL, Minvielle S, Moreau P; Intergroupe
Francophone du Myélome.Hematology Laboratory,
University Hospital, and Inserm U892, Nantes,
France. havetloiseau@chu-nantes.fr
Abstract
Many trials in myeloma are stratified on
cytogenetic abnormalities. Among them, the most
commonly chosen are the t(4;14), the del(17p),
and the t(14;16). If data are well established
for t(4;14) and del(17p), very few data support
the use of t(14;16). To address this issue, we
retrospectively analyzed 1003 patients with
newly diagnosed myeloma for this abnormality. We
identified 32 patients with the t(14;16).
Compared with patients lacking the t(14;16), we
did not observe any difference in overall
survival (P = .28). Moreover, in multivariate
analyses, the t(14;16) was not prognostic (P =
.39). In conclusion, our data do not support the
use of t(14;16)-specific probes in the
diagnostic panels of multiple myeloma.
- PMID: 20962323 [PubMed - indexed for
MEDLINE]